SEROLOGICAL PARAMETERS AS MARKERS FOR ACTIVE TUBERCULOSIS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS
Acta Innovations · 07.11.2026 · 64 (3s)
DOI: 10.62441/actainnovations.vi.3733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Innovations, online erschienen am 07.11.2026.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (DM) burden is increasing globally and many with type 2 DM are at increased risk especially in tuberculosis (TB) endemic countries like India. As TB diagnosis requires expensive tests, we undertook this case control study to assess parameters which could serve as markers for TB screening in patients with type 2 DM.
Method
In this study, 75 patients with type 2 DM and TB and 75 patients with type 2 DM without TB as controls were recruited. Serum levels of C-reactive protein (CRP) and vitamin D and the cytokines IL-10, IL-12, IL-17a, IFN-γ and TNF-α were estimated.
Result
Multivariate analysis demonstrated cases had higher CRP (AOR: 19.71; 95% CI: 2.76-140.31) and lower Vitamin D (AOR: 6.00; 95% CI: 1.09-32.94) respectively. A 10 kg difference in weight was also observed between cases and controls (p value: 0.019).
Conclusion
CRP and vitamin D levels varied significantly between cases and controls. Therefore, CRP, and vitamin D can be used as rapid and cost effective markers for active TB screening among patients with type 2 DM.
Zitieren
APA
(2026). SEROLOGICAL PARAMETERS AS MARKERS FOR ACTIVE TUBERCULOSIS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS. Acta Innovations, 64(3s). https://doi.org/10.62441/actainnovations.vi.3733
Vancouver
SEROLOGICAL PARAMETERS AS MARKERS FOR ACTIVE TUBERCULOSIS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS. Acta Innovations. 2026;64(3s). doi:10.62441/actainnovations.vi.3733
BibTeX
@article{euvimed2026,
title = {SEROLOGICAL PARAMETERS AS MARKERS FOR ACTIVE TUBERCULOSIS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS},
journal = {Acta Innovations},
year = {2026},
volume = {64},
number = {3s},
doi = {10.62441/actainnovations.vi.3733}
}
EUVIMED